We are THRILLED to have been awarded ‘best biotech start-up’ as part of the OBN (UK) Ltd Awards! The award is really a reflection of our fantastic, dedicated and diverse team - all of whom have contributed to making this possible.
#biotech #OBNAwards #startups
Alchemab partnering with AstraZeneca to advance prostate cancer therapies
#antibodies #drugdiscovery #prostatecancer #biotech
lnkd.in/ddBWh-H
We are thrilled to announce that we’ve raised £60m ($82m) in Series A funding led by RA Capital Management, with Lightstone Ventures and DHVC, joined by existing investors DCVC Bio, Dementia Discovery Fund and SV Health Investors who led the Seed round.
lnkd.in/dX7YgnD
Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease with Innovate UK grant
Exciting scientific and advanced analytic/bioinformatic opportunities to join the team – see
lnkd.in/d99PXQ6
lnkd.in/dgahkxH
We’re excited to announce our partnership with @IMI_EPAD! Together we will uncover new science and further the discovery of innovative treatments for Alzheimer’s Disease
The EPAD Bioresource consists of over 100,000 samples. We’ve sent out our first batch of samples to an external partner @alchemabtx. We’re excited that the Longitudinal Cohort Study continues to be an important resource which generates new #data for #Alzheimer’s disease #research
Delighted to have been added to the list of most disruptive companies in Cambridge - bit.ly/2K3056R
@businessweekly - thank you for the recognition!
Ten companies promoted to our list of the most disruptive life science and technology companies in Cambridge – The Killer50 bit.ly/2K3MZpV Killer50 companies have been involved in transactions worth more than $46.2bn in the last 12 months.
Very proud to feature two of Alchemab's team in this year’s Movers and Shakers in BioBusiness report, Jane Osbourn OBE and Olivia Cavlan.
Congratulations to Miranda Weston-Smith and the BioBeat team for compiling such a super report!
lnkd.in/dmdGUKC
Released today by @BioBeatUK, the 2020 Movers and Shakers in BioBusiness report highlights 30 examples of leaders in the UK bioscience sector.
Congratulations to the scientists, financial experts, collaborators, innovators, and infrastructure specialists.
mws-consulting.co.uk/publica…
Alchemab Therapeutics retweeted
The UK BIA #AntibodyTaskforce is a world-leading consortium of biotech companies, charities and academia based across the UK who share a joint commitment to help fight the #COVID19 pandemic. #COVID19Antibodies
Find out more👇
biacovid19.org/antibodies.ht…
Alchemab Therapeutics retweeted
Today we announce that the UK BIA #AntibodyTaskforce has identified antibodies with great potential to treat and protect against #COVID19, differentiated antibody combinations will be taken forward for further development as an antibody cocktail.👇
bia.me/37Ojv9b
We are delighted to announce a partnership between Alchemab and the Alberta Machine Intelligence Institute (Amii), a global leader in machine intelligence .
amii.ca/latest-from-amii/med…
Alchemab is delighted to be nominated as a finalist in the ‘Best Start-Up Biotech’ category for this year’s OBN Awards which recognises outstanding achievement in life sciences. Huge congratulations to our super team for their hard work and dedication over the last few months!
Jane Osbourn OBE, our CSO, will be speaking as the next guest on Rock Stars of R&D!
See details below if you’d like to join to listen this Friday, August 14, 2020 at 7pm BST: lnkd.in/dt7b94w
Alchemab is proud to be part of the Oxford BioEscalator cohort working on therapeutics against #COVID19
bioescalator.ox.ac.uk/news/a…
Aglie start-ups partner with academics to find covid-19 solutions @BioEscalator @NucleomeTx @DM_Jeziorska @alchemabtx #Hutanodiagnostics @OxfordMedSci @OxUInnovation @OxfordshireLEP @enterprisingox @Dunn_School @UnivofGh @MRC_WIMM #COVID19 #innovation
bioescalator.ox.ac.uk/news/a…
